Muliang Viagoo Technology Inc
Change company Symbol lookup
Select an option...
MULG Muliang Viagoo Technology Inc
MJ ETFMG Alternative Harvest ETF
NGG National Grid PLC
MDXG MiMedx Group Inc
GOGR Go Green Global Technologies Corp
APINX AMG Beutel Goodman International Equity Fund - Class N
SVBL Silver Bull Resources Inc
MYMD MyMD Pharmaceuticals Inc
TDS-U Telephone and Data Systems Inc
DOC Physicians Realty Trust
Go

Materials : Chemicals |
Based in China
Company profile

Muliang Viagoo Technology Inc, formerly Muliang Agritech Inc is a China-based company principally engaged in the manufacturing and distribution of organic fertilizer and the sales of agricultural products. The Company is engaged in the processing of crop straw (including corn, rice, wheat, cotton, and other crops) into organic nutritious fertilizer rich in small molecules. The Company distributes organic fertilizer products under its brand names Zongbao, Fukang and Muliang. The Company is also engaged in growing and selling agricultural products such as apples and providing logistics services.

Price
Delayed
$7.00
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
10

Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022

7:12 am ET November 8, 2022 (Globe Newswire) Print
Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022GlobeNewswireNovember 08, 2022

WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the third quarter ended September 30, 2022, before the financial markets open on Monday, November 14, 2022.

The Company's management team will host a conference call at 8:00 a.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0789 in the U.S. or 1-201-689-8562 outside the U.S. and ask for the Viridian call. To access the live webcast, please visit the "Events" page in the Investors section of the Viridian Therapeutics website. Following the live webcast, the archived call will be available on the website.

Monday, November 14 @ 8:00 a.m. ET
Domestic:1-877-407-0789
International:1-201-689-8562
Conference ID:13732927
Webcast:Webcast Link



About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies. Viridian's most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Viridian is based in Waltham, Massachusetts.

Investor and Media Contact:

John Jordan

Viridian Therapeutics

Vice President, Investor Relations

& Corporate Communications

617-272-4691

IR@viridiantherapeutics.com



Primary Logo

comtex tracking

COMTEX_418390714/2010/2022-11-08T07:12:26

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.